Tonghua Dongbao Pharmaceuticals (SHA: 600867), a China-based pharmaceutical company, has announced that the first patient has been dosed in a Phase IIa clinical study for its dual-targeted drug candidate, THDBH151, which is being evaluated for the treatment of gout.
THDBH151 is designed to target both xanthine oxidase (XO) and the renal tubular urate transporter (URAT1). The drug candidate works by inhibiting XO, thereby reducing the production of uric acid, and simultaneously inhibiting the reabsorption of uric acid by renal tubular URAT1 transporter, leading to accelerated uric acid excretion. This dual-action mechanism aims to enhance efficacy and minimize side effects, potentially improving patient compliance. Tonghua Dongbao’s THDBH151 is the first molecule in China to reach the Phase II stage of trials for this indication.- Flcube.com
